Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
VAXNEUVANCE (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
VAXNEUVANCE
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
pneumococcal purified capsular polysaccharides
Registration type
NCE/NBE
Indication
VAXNEUVANCE (suspension for injection) is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F) in adults 18 years of age and older.
VAXNEUVANCE may not prevent disease caused by S. pneumonia> serotypes that are not contained in the vaccine.
The use of VAXNEUVANCE should be guided by official recommendations.